| nr |
titel |
auteur |
tijdschrift |
jaar |
jaarg. |
afl. |
pagina('s) |
type |
| 1 |
Adjuvant radiation therapy in small ductal carcinoma in situ
|
Cho, Won Kyung
|
|
2019
|
43 |
C |
p. 55-58
|
artikel
|
| 2 |
Agreement between digital breast tomosynthesis and pathologic tumour size for staging breast cancer, and comparison with standard mammography
|
Marinovich, M. Luke
|
|
2019
|
43 |
C |
p. 59-66
|
artikel
|
| 3 |
A PALB2 truncating mutation: Implication in cancer prevention and therapy of Hereditary Breast and Ovarian Cancer
|
Velázquez, Carolina
|
|
2019
|
43 |
C |
p. 91-96
|
artikel
|
| 4 |
Category “viewpoints and debates” Is trastuzumab as a single agent obsolete in early breast cancer? Yes
|
Bonnefoi, Hervé
|
|
2019
|
43 |
C |
p. 146-148
|
artikel
|
| 5 |
Circulating renin-angiotensin system-regulating specific aminopeptidase activities in pre- and post- menopausal women with breast cancer treated or not with neoadyuvant chemotherapy. A two years follow up study
|
Ramírez-Exposito, María Jesús
|
|
2019
|
43 |
C |
p. 28-30
|
artikel
|
| 6 |
Clinico-pathological characteristics among South African women with breast cancer receiving anti-retroviral therapy for HIV
|
Phakathi, Boitumelo
|
|
2019
|
43 |
C |
p. 123-129
|
artikel
|
| 7 |
Clinicopathological characteristics of metaplastic breast cancer – analysis of the basic immunohistochemical profile and comparison with other invasive breast cancer types
|
Budzik, M.P.
|
|
2019
|
43 |
C |
p. 135-141
|
artikel
|
| 8 |
Consumer and clinician perspectives on personalising breast cancer prevention information
|
Keogh, L.A.
|
|
2019
|
43 |
C |
p. 39-47
|
artikel
|
| 9 |
Corrigendum to “Quality of life evolution in elderly survivors with localized breast cancer treated with radiotherapy over a three-year follow-up” [Breast 41 (October 2018) 74–81]
|
Arraras, Juan Ignacio
|
|
2019
|
43 |
C |
p. 7
|
artikel
|
| 10 |
EarlyR signature predicts response to neoadjuvant chemotherapy in breast cancer
|
Buechler, Steven A.
|
|
2019
|
43 |
C |
p. 74-80
|
artikel
|
| 11 |
Effects of adjuvant chemotherapy in T1N0M0 triple-negative breast cancer
|
Ren, Yi-Xing
|
|
2019
|
43 |
C |
p. 97-104
|
artikel
|
| 12 |
Estimation of the benefit and harms of including clinical breast examination in an organized breast screening program
|
Jiang, Huan
|
|
2019
|
43 |
C |
p. 105-112
|
artikel
|
| 13 |
Hepatic arterial therapy with oxaliplatin and systemic capecitabine for patients with liver metastases from breast cancer
|
Lindgaard, S.C.
|
|
2019
|
43 |
C |
p. 113-119
|
artikel
|
| 14 |
How to become a breast cancer specialist in 2018: The point of view of the second cohort of the Certificate of Competence in Breast Cancer (CCB2)
|
Montagna, Giacomo
|
|
2019
|
43 |
C |
p. 18-21
|
artikel
|
| 15 |
Is trastuzumab as a single agent obsolete in early breast cancer? No
|
Bianchini, Giampaolo
|
|
2019
|
43 |
C |
p. 142-145
|
artikel
|
| 16 |
MiRNA-27a sensitizes breast cancer cells to treatment with Selective Estrogen Receptor Modulators
|
Ljepoja, Bojan
|
|
2019
|
43 |
C |
p. 31-38
|
artikel
|
| 17 |
Outcomes of pleomorphic lobular carcinoma versus invasive lobular carcinoma
|
Haque, Waqar
|
|
2019
|
43 |
C |
p. 67-73
|
artikel
|
| 18 |
Phyllodes tumors of the breast. The treatment results for 340 patients from a single cancer centre
|
Mitus, J.W.
|
|
2019
|
43 |
C |
p. 85-90
|
artikel
|
| 19 |
Pure or mixed type invasive lobular carcinoma; are they different from each other?
|
Altundag, Kadri
|
|
2019
|
43 |
C |
p. 151
|
artikel
|
| 20 |
Reply to the letter “Pure or mixed type invasive lobular carcinoma; are they different from each other?”
|
Haque, Waqar
|
|
2019
|
43 |
C |
p. 151-152
|
artikel
|
| 21 |
Reply to the letter “Safety of fertility preservation in women with breast cancer”
|
Lambertini, Matteo
|
|
2019
|
43 |
C |
p. 149-150
|
artikel
|
| 22 |
Ribociclib in hormone-receptor-positive advanced breast cancer: Establishing a value-based cost in China
|
Wan, XiaoMin
|
|
2019
|
43 |
C |
p. 1-6
|
artikel
|
| 23 |
Risk of cardiac disease after adjuvant radiation therapy among breast cancer survivors
|
Chang, Jee Suk
|
|
2019
|
43 |
C |
p. 48-54
|
artikel
|
| 24 |
Safety of fertility preservation in women with breast cancer
|
Rodriguez-Wallberg, Kenny A.
|
|
2019
|
43 |
C |
p. 149
|
artikel
|
| 25 |
Sexuality, a topic that surgeons should discuss with women before risk-reducing mastectomy and breast reconstruction
|
Dikmans, Rieky E.G.
|
|
2019
|
43 |
C |
p. 120-122
|
artikel
|
| 26 |
Targeting CDK4/6 pathways and beyond in breast cancer
|
Ribnikar, Domen
|
|
2019
|
43 |
C |
p. 8-17
|
artikel
|
| 27 |
The role of histone deacetylase inhibitors in metastatic breast cancer
|
Zucchetti, Bruna
|
|
2019
|
43 |
C |
p. 130-134
|
artikel
|
| 28 |
Treatment patterns and clinical outcomes among patients receiving palbociclib in combination with an aromatase inhibitor or fulvestrant for HR+/HER2-negative advanced/metastatic breast cancer in real-world settings in the US: Results from the IRIS study
|
Taylor-Stokes, Gavin
|
|
2019
|
43 |
C |
p. 22-27
|
artikel
|
| 29 |
Why upfront use of CDK inhibitors for the treatment of advanced breast cancer may be wasteful, and how we can increase their value
|
Niraula, Saroj
|
|
2019
|
43 |
C |
p. 81-84
|
artikel
|
Tijdschrift beschrijving